Private Label Benzoyl Peroxide Spot Treatment Manufacturer Low MOQ

Does a private label benzoyl peroxide product need FDA approval?

By Blake Mereby · Last reviewed October 4, 2026

Benzoyl peroxide acne treatments are regulated as OTC drug products in the United States, not as cosmetics. They do not require pre-market approval (like a prescription NDA) but they must comply with the FDA's OTC Drug Monograph system — specifically the acne monograph codified at 21 CFR Part 333, Subpart C. Compliance with that monograph is what allows you to market the product without a full NDA, but it is not optional — failure to comply constitutes marketing an unapproved new drug.

What the monograph dictates: permitted active ingredients and concentrations (BP at 2.5%, 5%, or 10%), permitted dosage forms (gels, creams, lotions, soaps, and pads), required labeling language including specific warning statements about skin and eye irritation, directions for use, and the precise way the active ingredient must be declared on the Drug Facts panel. Your product label must include a Drug Facts box formatted per 21 CFR 201.66 — this is non-negotiable and is entirely different from a cosmetics ingredient panel.

The manufacturer producing your product must be registered with the FDA as a drug establishment under 21 CFR Part 207 and must operate under drug cGMP regulations (21 CFR Part 211). Many cosmetic contract manufacturers are not registered or equipped for this. Verifying FDA drug establishment registration is step one before any commercial conversation.

You, as the brand owner (the "labeler"), also have FDA registration and listing obligations. You must list your OTC drug product with the FDA via the SPL (Structured Product Labeling) system. This is a technical submission process — most founders work with a regulatory affairs consultant or a manufacturer whose team handles this as a service. Expect $1,500–$5,000 in regulatory consulting fees for a first-time OTC listing.

A significant regulatory development: the FDA Omnibus Reform Act of 2022 (DOGE, formerly OTC Monograph Reform) modernized how the monograph system works and introduced administrative orders. Brands and manufacturers should track any updates to the acne active ingredient monograph, particularly following the FDA's 2019 proposed rule that questioned the GRASE (generally recognized as safe and effective) status of higher-concentration BP. As of the current framework, 2.5% and 5% concentrations remain unambiguously GRASE; brands launching 10% formulas should consult regulatory counsel for the latest status.

If you plan to sell in the EU, the regulatory picture is completely different — BP spot treatments are classified and regulated under EU cosmetics regulation (EC 1223/2009) at certain concentrations, while others may require medicinal classification. Country-by-country guidance from a European regulatory consultant is essential before any EU launch.

AJ Cosmo Labs connects indie founders with OTC-experienced contract manufacturers and regulatory consultants who understand these requirements, so you're not navigating the Drug Facts panel alone.

Read the full guide on Private Label Benzoyl Peroxide Spot Treatment Manufacturer Low MOQ →

More about Private Label Benzoyl Peroxide Spot Treatment Manufacturer Low MOQ

Tell us about your product

Tell us what you're selling and where. You can hire a vetted cosmetic chemist on AJ Cosmo Labs to review your formula and labeling. Starting is free.

Free to start · no credit card · continue in your browser or the iPhone app.

Have a product idea?

Connect with vetted cosmetic chemists and custom labs on AJ Cosmo Labs.

Get on the App Store Open the web app